Quinapril for treatment of hypertension in Turkey - Dose titration and diuretic combination treatment strategies

Basit Öğe Kaydı
dc.contributor.authorYener, Gul
dc.contributor.authorAran, Sinan
dc.contributor.authorBahceci, Mithat
dc.contributor.authorOzdemir, Kurtulus
dc.contributor.authorGultekin, Fusun
dc.contributor.authorLowe, Wing
dc.date.accessioned2024-04-24T17:18:31Z
dc.date.available2024-04-24T17:18:31Z
dc.date.issued2007
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground and objective: Recently the PatenT (Prevalence, awareness, treatment and control of hypertension in Turkey) study showed that while the prevalence of hypertension in Turkey is high, effective control of BP is infrequently achieved. This study investigated the efficacy and safety of quinapril (as monotherapy or in combination with hydrochlorothiazide [HCTZ]) for achieving BP control (target < 140/90mm Hg) in Turkish subjects with mild to moderate hypertension. Methods: Two-hundred male and female outpatients aged 19-65 years with mild to moderate hypertension (stage I or II, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 7 guidelines) entered this 12-week, open-label study. All subjects received quinapril 20 mg/day for 6 weeks. If BP targets were achieved at week 6, responders were maintained on 20 mg/day-1 if BP targets were not achieved, non-responders were randomised to quinapril 40 mg/day or quinapril 20 mg/day + HCTZ 12.5 mg/day for the remainder of the study. Results: After 6 weeks, 63% of subjects achieved BP targets, and 82% of week-6 responders who continued on quinapril 20 mg/day maintained BP targets at week 12. Of the non-responders, 50% and 52% randomised to quinapril 40 mg/day or quinapril 20 mg/day + HCTZ 12.5 mg/day, respectively, went on to achieve BP targets by week 12. Safety was not compromised with increased dosages or use of combination therapy. Conclusion: Quinapril was an effective and safe treatment for achieving and maintaining recommended BP targets in this sample population. These findings will provide clinicians in Turkey with valuable data on the use of quinapril for effective control and management of hypertension.en_US
dc.identifier.doi10.2165/00044011-200727090-00003
dc.identifier.endpage622en_US
dc.identifier.issn1173-2563
dc.identifier.issn1179-1918
dc.identifier.issue9en_US
dc.identifier.pmid17705570
dc.identifier.scopus2-s2.0-34548134879
dc.identifier.scopusqualityQ2
dc.identifier.startpage613en_US
dc.identifier.urihttps://doi.org/10.2165/00044011-200727090-00003
dc.identifier.urihttps://hdl.handle.net/11468/18812
dc.identifier.volume27en_US
dc.identifier.wosWOS:000249359500003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAdis Int Ltden_US
dc.relation.ispartofClinical Drug Investigation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleQuinapril for treatment of hypertension in Turkey - Dose titration and diuretic combination treatment strategiesen_US
dc.titleQuinapril for treatment of hypertension in Turkey - Dose titration and diuretic combination treatment strategies
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu